New Age Diagnostics, Inc. $("$NEW AGE"$)$ was incorporated in $2018$ with the Entrepreneurs issuing

themselves $5,000,000$ of common shares. In $2019,$ NEW AGE issued SAFE Contracts and raised

$$1,000,000.$ The SAFE Contracts had a Floor of $$10$ million, a Ceiling of $$30$ million, and would $$convert$$

into a Series A Financing of at least $$10$ million in new capital at a $20\%$ discount to the Series A price.

In $2021$ NEW AGE completed a Series A round of financing of $$15$ million by issuing a

Convertible Preferred Shares with a $1$x Liquidation Preference, a Full$-$Ratchet Anti$-$Dilution Provision and

a $7\%$ Cumulative Dividend Rate; at a Pre$-$Money Valuation of $$35$ million.

What is the Capital Structure of NEW AGE assuming that it has a Series B Term Sheet from a new VC with

$$20$ million of new capital in Participating Preferred Shares with a $1$x Liquidation Preference, a Full$-$

Ratchet Anti$-$Dilution Provision and a $5\%$ Cumulative Dividend Rate; at a Pre$-$Money Value of $$65$

million?

$1.$ What is the series A price?

$2.$ What is the SAFE conversion price?

$3.$ How many series A shares are issued to the SAFE investors?

$4.$ How many series B shares are issued to the series B investors?